非小細胞肺がん成人患者におけるTAK-788の研究

基本情報

NCT ID

NCT02716116

ステータス

実施中（募集終了）

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

334

治験依頼者名

Takeda

概要

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)